Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in treatment-resistant CIDP with anti-nerve reactivity evaluation
2018-001347-31Phase 2Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Humanitas Research Hospital. Started Jan 2021; status: completed.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2018-001347-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001347-31.